UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Annals of oncology, 2008-02, Vol.19 (2), p.362-369

2008

Volltextzugriff (PDF)

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

Journal of clinical oncology, 1997-10, Vol.15 (10), p.3185-3191

1997

Volltextzugriff (PDF)

Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer

Critical reviews in oncology/hematology, 2001-02, Vol.37 (2), p.115-120

2001

Volltextzugriff (PDF)

Cerebral metastases in malignant mesothelioma: a case report

European journal of cancer care, 1999-06, Vol.8 (2), p.104-106

1999

Volltextzugriff (PDF)

Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis

European journal of cancer & clinical oncology, 1990, Vol.26 (6), p.691-694

1990

Volltextzugriff (PDF)

Cerebral metastases in malignant mesothelioma: a case report

European journal of cancer care, 1999-06, Vol.8 (2), p.104-106

1999

Volltextzugriff (PDF)

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Cancer discovery, 2014-09, Vol.4 (9), p.1046-1061

2014

Volltextzugriff (PDF)

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

Annals of oncology, 2016-12, Vol.27 (12), p.2268-2274

2016

Volltextzugriff (PDF)

SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer

Oncogene, 2017-07, Vol.36 (30), p.4288-4298

2017

Volltextzugriff (PDF)

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Clinical cancer research, 2012-06, Vol.18 (11), p.3163-3169

2012

Volltextzugriff (PDF)

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

British journal of cancer, 2012-01, Vol.106 (3), p.468-474

2012

Volltextzugriff (PDF)

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies

Investigational new drugs, 2015-06, Vol.33 (3), p.679-690

2015

Volltextzugriff (PDF)

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

British journal of cancer, 2009-11, Vol.101 (10), p.1724-1730

2009

Volltextzugriff (PDF)

Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma

Journal of clinical oncology, 2003-07, Vol.21 (13), p.2551-2557

2003

Volltextzugriff (PDF)

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

Investigational new drugs, 2016-06, Vol.34 (3), p.329-337

2016

Volltextzugriff (PDF)

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

Annals of oncology, 2010-04, Vol.21 (4), p.884-894

2010

Volltextzugriff (PDF)

Lomeguatrib, a Potent Inhibitor of O 6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

Clinical cancer research, 2006-03, Vol.12 (5), p.1577-1584

2006

Volltextzugriff (PDF)

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study

Annals of oncology, 2010-11, Vol.21 (11), p.2233-2239

2010

Volltextzugriff (PDF)

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

British journal of cancer, 2008-05, Vol.98 (10), p.1614-1618

2008

Volltextzugriff (PDF)

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC

British journal of cancer, 2010-01, Vol.102 (1), p.97-103

2010

Volltextzugriff (PDF)

Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

British journal of cancer, 2006-07, Vol.95 (1), p.42-48

2006

Volltextzugriff (PDF)

Urokinase‐type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer‐specific survival and potential therapeutic targets

International journal of cancer, 2000-09, Vol.89 (5), p.431-439

2000

Volltextzugriff (PDF)

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma

British journal of cancer, 2009-04, Vol.100 (8), p.1245-1249

2009

Volltextzugriff (PDF)

Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma

Cancer, 2003-08, Vol.98 (3), p.542-553

2003

Volltextzugriff (PDF)

Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles

Anti-cancer drugs, 2011-01, Vol.22 (1), p.24-34

2011

Volltextzugriff (PDF)

1 – 25 von 42

Suche als RSS-Feed

Aktive Filter

ThemaOncology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(41)
Mit Volltextzugriff
(41)

Publikationsform

Artikel
(42)

Sprache

Englisch
(42)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(39)
Science & Technology
(39)
Humans
(37)
Female
(29)
Middle Aged
(24)
Biological And Medical Sciences
(23)
Medical Sciences
(23)
Male
(22)
Aged
(21)
Adult
(20)
Pharmacology. Drug Treatments
(13)
Antineoplastic Agents
(12)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(12)
Antineoplastic Combined Chemotherapy Protocols - Adverse Effects
(11)
Chemotherapy
(11)
Dose-Response Relationship, Drug
(11)
Lung Neoplasms - Drug Therapy
(10)
Tumors
(10)
Treatment Outcome
(9)

14 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer

Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial

Caelyx (stealth liposomal doxorubicin) in the treatment of advanced breast cancer

Cerebral metastases in malignant mesothelioma: a case report

Ifosfamide, doxorubicin and etoposide in small cell lung cancer patients with poor prognosis

Cerebral metastases in malignant mesothelioma: a case report

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

A phase I, pharmacokinetic and pharmacodynamic study of GSK2256098, a focal adhesion kinase inhibitor, in patients with advanced solid tumors

SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer

Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer

Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours

AZD3514, an oral selective androgen receptor down-regulator in patients with castration-resistant prostate cancer – results of two parallel first-in-human phase I studies

Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

Randomized Phase II Study of Temozolomide Given Every 8 Hours or Daily With Either Interferon Alfa-2b or Thalidomide in Metastatic Malignant Melanoma

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors

Safety, tolerability, pharmacokinetics and pharmacodynamics of the oral cyclin-dependent kinase inhibitor AZD5438 when administered at intermittent and continuous dosing schedules in patients with advanced solid tumours

Lomeguatrib, a Potent Inhibitor of O 6-Alkylguanine-DNA-Alkyltransferase: Phase I Safety, Pharmacodynamic, and Pharmacokinetic Trial and Evaluation in Combination with Temozolomide in Patients with Advanced Solid Tumors

Erlotinib in combination with pemetrexed for patients with advanced non-small-cell lung cancer (NSCLC): a phase I dose-finding study

A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer

A small molecule inhibitor of XIAP induces apoptosis and synergises with vinorelbine and cisplatin in NSCLC

Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

Urokinase‐type plasminogen activator and its receptor in colorectal cancer: Independent prognostic factors of metastasis and cancer‐specific survival and potential therapeutic targets

A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma

Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma

Preclinical evaluation of novel, all-in-one formulations of 5-fluorouracil and folinic acid with reduced toxicity profiles

Aktive Filter

Suchergebnisse filtern